

ASX / Media Release

28 July 2010

RHT: Liver Fibrosis and Fat Test Update

Resonance Health announces that it has received strong support from the clinical community for the preliminary results of its MRI liver fibrosis and fat tests and the Company is now seeking partners for the next stage of development.

Following the announcement on 7 May 2010 of the results of the first phase of product development of a test to assess liver fibrosis and liver fat using MRI, the Company has conducted in depth analysis of competing technologies and market research involving international key medical opinion leaders. There has been a very positive response to the initial results of the MRI test for liver fibrosis and combined with the ability to measure liver fat would offer a significant competitive advantage over other products available in the market.

As a result, Resonance Health is now actively seeking partners to fund and further develop its MRI based tests for measuring liver fibrosis and liver fat.

Pharmaceutical companies involved in the development of therapeutic solutions for non-alcoholic fatty liver disease and anti-fibrogenics and antiviral therapies for patients with hepatitis, will be encouraged by a non-invasive imaging alternative to a liver biopsy. These tests could offer significant improvement to patient recruitment in some clinical trials where a liver biopsy would otherwise be required and provides a better alternative for patients, often requiring repeat measurement.

Liza Dunne, the Managing Director of Resonance Health said "This new liver fibrosis and fat test represents an excellent opportunity for growth for the Company and an attractive market to complement our existing expertise and relationships with liver specialists that have been developed through the international rollout of our successful FerriScan test."

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Prof Tim St Pierre
Chief Scientific Officer
T: +61 8 9286 5300
E: tims@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing radiological image analysis services for the clinical and research communities with a strong clinical focus on the liver. Its patented technology FerriScan[®] provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. The Company continues to invest in research and development into other quantitative radiological imaging technologies.